Pharmaceutical Companies Strengthen Intellectual Property Protections in Response to Chinese Competition
In light of increasing competition from China, drugmakers are tightening their intellectual property safeguards. This shift comes amid changes in FDA regulations and ongoing discussions about animal testing in biotech.